Video Journal of Hematology & Hematological Oncology (VJHemOnc)’s Post

Introducing: VJ in Practice 🧫 🔬🩸 We're excited to share some exclusive INTERACTIVE #hemepath #casestudies with you! 🔦 Learn more about: 🩸 Approaching diagnosis and #diseaseclassification 🩸 Treatment options for newly diagnosed #AML 🩸 The importance of recurrent #geneticalterations when making #treatment decisions With expert insight from Sanam Loghavi and Naval Daver (MD Anderson Cancer Center) 🔦 Up for the challenge? Get started 👉 https://ow.ly/GbrX50R88X5 Big thank you to Sanam Loghavi for working on these with us! 🧡 #VJHemOnc #Hematologycasestudy #Leusm #AMLsm #AMLCaseStudy #InteractiveCaseStudy #HealthcareInnovation #MedicalEducation

September is #BloodCancer Awareness Month and we are passionate about bringing you the latest #news, #education & cutting-edge updates🩸 📣 Check out this interview from COMy 2024 with Meral Beksaç, MD, PhD, Ankara University. She talks on unmet treatment needs in subgroups of patients with #multiplemyeloma 🎥 She highlights several key patient subgroups: those with #extramedullary disease, who showed inferior response rates in the EMN19 trial (NCT04166565); patients with #renal impairment; patients with #bonelesions; and those facing emerging infections following #CARTtreatment💡 Learn more 👉 https://lnkd.in/ekar2m4X #BloodCancerAwarenessMonth #Hematologynews #VJHemOnc #MMsm

Today is #MPN Awareness Day!🩸 📣 We recently heard from Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, on the use of symptom response as an endpoint in #myelofibrosis (MF) #clinica trials, outlining some factors that should be considered when assessing symptom response 🔦 Additionally, Dr Mesa comments on whether trials should be conducted over a longer period than the often selected 24-week window 🤔 Learn more 👉 https://ow.ly/KoYb50SUtXP #MPNAwarenessDay #MPNsm #BloodCancerAwarenessMonth #VJHemOnc

Want to learn about advances in the treatment of #BPDCN, including the role of #tagraxofusp & other #CD123-directed agents? 🤔 🗞️🩸 Explore our most recent article 👉 https://lnkd.in/exFNwe8J Covering: 🌟 An Overview Of The Biology Of #BPDCN 🌟 #Tagraxofusp 🌟 #Pivekimab Sunirine And #CARTCells 🌟 Combination Approaches With #Venetoclax #VJHemOnc #BPDCN #RareDiseases #ImmunoOnc Andrew Lane, MD, PhD Naveen Pemmaraju, MD

NEW #podcast episode: 'Global perspectives on #bloodcancers: addressing disparities in awareness, diagnosis, and treatment' 🎧🩸🌍 Welcome to the first episode of our #BloodCancerAwarenessMonth series! ✨ Leading experts discuss: challenges that exist in the management of #bloodcancers in India and programs that are in place to address these, racial disparities in the treatment of #multiplmyeloma in America, #socioeconomic and racial disparities in #myeloma trial recruitment and finally a survey investigating global disparities in access to treatment and resources for patients with #chroniclymphocyticleukemia in low-income countries 🔦 With: 🌟 Lalit Kumar, MD, MBBS, Artemis Hospital 🌟 Joseph Mikhael, MD, MEd, FRCPC, FACP, The Translational Genomics Research Institute (TGen) 🌟 Amrutha Sridhar, MBBS, University College London Hospitals NHS Foundation Trust 🌟 Brian Koffman, MDCM (retired), MS Ed, CLL Society Give it a listen 👉 https://lnkd.in/eNJajdjf #VJHemOnc #Hematologynews #BloodCancerAwareness #Leusm

September is #BloodCancer Awareness Month and we are passionate about bringing you the latest #news, #education & cutting-edge updates🩸 📣 Check out this interview with Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center on the importance of the #MDT to provide adequate treatment and care to patients with #amyloidosis Dr Milani explains that specialists including #cardiologists, #nephrologists, and #neurologists are essential to provide adequate treatment and supportive care 🩺 🧠💡 Learn more 👉 https://lnkd.in/eTvDRV_k #BloodCancerAwarenessMonth #Hematologynews #VJHemOnc #MMsm

What is the treatment schedule for #ruxolitinib in patients with MPNs, and how should response be assessed? 🤔 🩸 🎥 This important question was answered by Aaron Gerds, MD, MS, Cleveland Clinic in a recent interview In patients with #myelofibrosis (MF), the Response to #Ruxolitinib After 6 Months (RR6) prognostic model has been developed to allow physicians to determine which #ruxolitinib-treated patients are exhibiting sub-optimal responses to the agent and may benefit from a treatment shift 🔦 Learn more 👉 https://lnkd.in/eEQCewaF #MPNsm #VJHemOnc #MPNWorkshopNC #Hematologynews

September is #BloodCancer Awareness Month and we are passionate about bringing you the latest #news, #education & cutting-edge updates🩸 📣 Check out our NEW Trial In Focus feature: #NUTRIVENTION – #dietary evidence in #cancercare 🔍 🍴 #Multiplemyeloma is the second most common #hematologicalmalignancy and remains an incurable disease. Diet has been linked to #myelomapathogenesis, making it an important factor to study in this disease setting 🍎 🥑 Additionally, known risk factors for #plasmacell disorders include #obesity, high #leptin levels, high #insulin levels, and diets lacking in #plantbased foods. There is also evidence that #microbiome dysbiosis plays a role in patients with these disorders 🔦 Explore the feature to learn about the #NUTRIVENTIONtrial from lead investigator Urvi Shah, MD, Memorial Sloan Kettering Cancer Center 👉 https://lnkd.in/eezpt8uM #BloodCancerAwarenessMonth #Hematologynews #VJHemOnc #MMsm